Taysha Gene Therapies (TSHA) News Today → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free TSHA Stock Alerts $3.11 +0.54 (+21.01%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 10:03 PM | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)May 15 at 5:38 PM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.57Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.57May 15 at 12:58 PM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Earnings ResultsTaysha Gene Therapies (NASDAQ:TSHA - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The company had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same period last year, the firm earned ($0.28) EPS.May 15 at 9:55 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Chemed (CHE), Acadia Healthcare (ACHC) and Taysha Gene Therapies (TSHA)May 15 at 9:33 AM | marketbeat.comTaysha Gene Therapies' (TSHA) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday.May 15 at 5:54 AM | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Jefferies Financial GroupMay 15 at 3:26 AM | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Buy" by BrokeragesMay 15 at 3:25 AM | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by BrokeragesTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned a consensus rating of "Buy" from the nine analysts that are covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy rating. The average 12-month price target among brokersMay 14 at 9:04 PM | investorplace.comTSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q1 2024May 14 at 6:53 PM | msn.comTaysha Gene Therapies upgraded at Jefferies on Rett Syndrome assetMay 14 at 4:01 PM | globenewswire.comTaysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14 at 1:07 PM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $2.40Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $2.40May 14 at 8:58 AM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Given Buy Rating at Jefferies Financial GroupJefferies Financial Group reissued a "buy" rating and issued a $8.00 price target (up from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday.May 13 at 6:01 PM | msn.comTaysha Gene Therapies Q1 2024 Earnings PreviewMay 12, 2024 | americanbankingnews.comTaysha Gene Therapies (TSHA) Scheduled to Post Quarterly Earnings on TuesdayMay 8, 2024 | marketbeat.comTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on TuesdayTaysha Gene Therapies (NASDAQ:TSHA) will be releasing earnings after the market closes on Tuesday, May 14, Zacks reports.May 7, 2024 | globenewswire.comTaysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14May 6, 2024 | americanbankingnews.comNeedham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA)May 3, 2024 | msn.comFDA grants RMAT designation to Taysha’s Rett syndrome gene therapyMay 3, 2024 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday.May 2, 2024 | globenewswire.comTaysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett SyndromeApril 30, 2024 | marketbeat.comTaysha Gene Therapies' (TSHA) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday.April 18, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday.April 15, 2024 | finance.yahoo.comCertain Biotech Investors Get an Early Look at Results. Is That Fair?April 15, 2024 | marketbeat.comVanguard Group Inc. Has $16.84 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Vanguard Group Inc. boosted its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 235.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,327,864 shares of the company's stock after purchasing an addApril 11, 2024 | markets.businessinsider.comImpact and Outlook: Taysha Gene Therapies Stock AnalysisApril 11, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday.April 10, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Up 3%Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 3%April 9, 2024 | msn.comTaysha draws bullish view at Piper Sandler on lead assetApril 9, 2024 | markets.businessinsider.comBuy Rating on Taysha Gene Therapies with TSHA-102 Poised to Transform Rett Syndrome Treatment and Drive Revenue GrowthApril 9, 2024 | markets.businessinsider.comEvaluating Taysha Gene Therapies: Insights From 7 Financial AnalystsApril 9, 2024 | marketbeat.comPiper Sandler Begins Coverage on Taysha Gene Therapies (NASDAQ:TSHA)Piper Sandler started coverage on Taysha Gene Therapies in a report on Tuesday. They issued an "overweight" rating and a $9.00 target price on the stock.April 5, 2024 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Up 5.1%Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 5.1%April 3, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.71Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.71March 26, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Down 2.6%Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 2.6%March 26, 2024 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by AnalystsTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned a consensus rating of "Buy" from the seven research firms that are covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among brMarch 21, 2024 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Canaccord Genuity GroupCanaccord Genuity Group reaffirmed a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday.March 21, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Sees Strong Trading Volume After Analyst UpgradeTaysha Gene Therapies (NASDAQ:TSHA) Sees Strong Trading Volume on Analyst UpgradeMarch 21, 2024 | markets.businessinsider.comBuy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study CatalystsMarch 21, 2024 | finance.yahoo.comTaysha Gene Therapies Full Year 2023 Earnings: Beats ExpectationsMarch 21, 2024 | marketbeat.comChardan Capital Raises Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $7.00Chardan Capital lifted their target price on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a "buy" rating in a report on Thursday.March 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Taysha Gene Therapies Amid Positive Clinical Progress and Robust Financial HealthMarch 20, 2024 | msn.comTaysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental DisorderMarch 20, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Taysha Gene Therapies Amid Clinical Progress and Financial StabilityMarch 20, 2024 | msn.comWhy Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving PremarketMarch 20, 2024 | msn.comTaysha Gene Therapies jumps after early data for Rett syndrome candidateMarch 20, 2024 | finance.yahoo.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Healthcare Takes A Big Step Forward With The Help Of AI (Ad)The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+. Click here to see why this small company is trusted by the Mayo Clinic TSHA Media Mentions By Week TSHA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSHA News Sentiment▼0.490.55▲Average Medical News Sentiment TSHA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSHA Articles This Week▼202▲TSHA Articles Average Week Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EDIT News CCCC News ADPT News VYGR News ITOS News LXEO News FATE News ALVO News ALLO News REPL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSHA) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportPharma Giant Makes Deal with a "Drug Smuggler"Behind the MarketsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
